^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPI-21668

    i
    Other names: BPI-21668
    Associations

    News

    Trials
    Company:
    Betta Pharma
    Drug class:
    PIK3CA inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 (clinicaltrials.gov)
    P1, N=60, Recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1 trial
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    BPI-21668